Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Pascal Thériault-Lauzier , Marco Spaziano , Beatriz Vaquerizo , et al Added: 3 years ago
Valvular Disease Aortic valve Severe symptomatic aortic stenosis (AS) bears a dismal prognosis. The mean survival is 2.0 to 4.7 years after the onset of angina, 0.8 to 3.8 years after the onset of syncope and 0.5 to 2.8 years after the onset of congestive heart failure.1 Surgical aortic valve replacement (SAVR) is the mainstay of treatment for these patients.2 In the last decade transcatheter… View more

Vascular Disease and Surgery

Imaging & Diagnostics
Author(s): Antonio L Bartorelli , Claudio Tondo Added: 3 years ago
On average, every 20 seconds someone in the US1 or in Europe2 has a stroke. This adds up to a total of about 1.7 million strokes per year in these two continents, affecting about 0.22% of the population each year. In the US alone, every four minutes someone dies from stroke, yielding a total mortality of about 140,000 deaths per year. As a result, stroke is the world’s third leading cause of… View more

Prevention & Chronic Conditions
Author(s): John A Kaufman Added: 3 years ago
Optional vena cava (VC) filters are filtration devices that can be placed percutaneously into the inferior VC (IVC) to provide protection from pulmonary embolism (PE). These devices can be either removed (retrievable filters) or altered in some way to no longer function as a filter while remaining in the IVC (convertible filters), although the latter are not yet commercially available. The… View more

Standards & Guidelines

Intervention
PFO-associated Stroke and COVID-19 Vaccination
Author(s): Maja Rojko , Natasa Cernic Suligoj , Metka Zorc , et al Added: 1 year ago

Heterogeneous Populations

COVID-19
Anti-thrombotic Therapy Following TAVI: UK and Ireland Consensus Statement
Author(s): Azfar Zaman , Bernard Prendergast , David Hildick-Smith , et al Added: 1 year ago

Anticoagulation
AHA 21: AXIOMATIC-TKR: Patients Treated with Milvexian Show Reduced Rate of Venous Thromboembolism
Author(s): Jeffrey Weitz Added: 2 years ago
Dr Jeffrey Weitz (Thrombosis & Atherosclerosis Research Institute, Ontario, CA) presents the results of the Axiomatic-TKR Study, a phase II dose-ranging study that aims to examine the effect of Milvexian versus Enoxaparin in the treatment of venous thromboembolism in patients undergoing total-knee replacement surgery.The study met its efficacy criteria, where the rate of thromboembolism was… View more

Vascular Disease and Surgery
Author(s): Andrew Archbold Added: 3 years ago
Patients who undergo coronary artery stenting require dual antiplatelet therapy (DAPT) in order to reduce their risk of stent thrombosis. Long-term oral anticoagulation (OAC) is indicated for the primary and secondary prevention of thrombotic events in patients with atrial fibrillation (AF), mechanical heart valves, intra-cardiac thrombus, venous thromboembolic disease and some hypercoagulable… View more

Anticoagulation

Prevention & Chronic Conditions
Dr Boris Schmidt is a Cardiologist specialising in Electrophysiology at Cardiologisches Centrum Bethanien in Frankfurt, Germany. Dr Boris Schmidt's scientific activities are focused on catheter ablation of atrial fibrillation and the development of novel single-shot technologies as well as interventional stroke prophylaxis. View more
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR
Author(s): Duk-Woo Park Added: 2 years ago
In this short interview, Dr Duk-Woo Park (Asan Medical Center, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial (NCT03284827). The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR. Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less… View more

Anticoagulation
Research Area(s) / Expertise: Job title: Director
Dr Claudio Tondo is the Chairman of the Heart Rhythm centre at Centro Cardiologico, University of Milan, Italy. Dr Tondo's interests range from clinical aspects of arrhythmias to genetics. View more